DEA Rescheduling Stalls as Cannabis Lawyers Face Regulatory Limbo

Administrative Limbo Extends Into Mid-2026

The DEA's proposed rule to reschedule cannabis to Schedule III hasn't advanced to a final rule despite nearly two years of procedural review. The agency accepted public comments through a notice-and-comment period that closed in late 2024, but no final determination has been issued. Administrative law judges continue reviewing objections filed by stakeholders ranging from state regulators to pharmaceutical trade groups.

The delay leaves cannabis operators in a legal gray zone. Schedule I classification still applies. That means federal prohibitions on interstate transport and banking access remain fully in force. Yet many state-licensed operators have begun preparing for Schedule III compliance frameworks that may never materialize in their current form—or may arrive in a shape nobody anticipated.

280E Tax Burden Remains Unresolved

Cannabis businesses continue paying effective tax rates exceeding 70% under IRC Section 280E, which disallows ordinary business deductions for Schedule I or II substances. Rescheduling to Schedule III would lift that restriction, but only after a final rule takes effect. Attorneys report clients are filing amended returns in anticipation of retroactive relief, a strategy the IRS hasn't endorsed.

Tax practitioners are advising conservatism, according to The National Law Review: file under current law, preserve records for potential refund claims, and don't assume retroactive application. That posture reflects uncertainty about whether the DEA will finalize the rule at all, or whether further delays push implementation into 2027 or beyond.

Interstate Commerce Planning on Hold

Multi-state operators can't move product across state lines under Schedule I, but Schedule III would theoretically permit interstate transfer with DEA registration. Legal teams are drafting compliance protocols for a post-rescheduling environment. No guidance exists. The DEA hasn't published a proposed framework for interstate cannabis commerce under Schedule III, leaving operators to guess at registration requirements, inspection protocols, and distribution controls.

Attorneys say clients are asking whether to invest in cross-border distribution infrastructure now or wait. The answer depends on timing nobody can predict. For context on the full rescheduling saga, see the CannIntel topic hub on DEA rescheduling.

State-Federal Conflict Persists

Thirty-eight states have legalized medical or adult-use cannabis, but federal Schedule I status still exposes operators to enforcement risk. Rescheduling wouldn't legalize cannabis. It would simply reclassify it as a controlled substance with accepted medical use and lower abuse potential. State programs would still operate in tension with federal law, though prosecution risk would likely decline.

Cannabis lawyers are advising clients that rescheduling isn't descheduling. Federal possession limits, manufacturing permits, and distribution controls would still apply. The Controlled Substances Act would still govern the supply chain, just under a different schedule with different procedural requirements.

Hemp and THCA Markets Face Separate Uncertainty

The 2018 Farm Bill exempted hemp—defined as cannabis with ≤0.3% delta-9 THC by dry weight—from CSA scheduling, but rescheduling could trigger new DEA scrutiny of hemp-derived intoxicating cannabinoids. Products like THCA flower and delta-8 THC currently operate in a statutory gap. If cannabis moves to Schedule III, the DEA may assert broader authority over all THC isomers, including those derived from legal hemp.

Attorneys practicing in the hemp space are watching for language in the final rule that addresses total THC versus delta-9 THC, decarboxylation, and post-harvest conversion. None of that has been clarified. The rescheduling docket doesn't directly address hemp, but enforcement posture could shift once the rule is final—assuming it ever arrives.

What Comes Next

The DEA hasn't announced a target date for a final rule, and no hearing schedule is public. Industry observers expect the process to extend into 2027 unless the agency accelerates review or political pressure forces a decision. Until then, cannabis lawyers are advising clients to operate under current law, preserve documentation for future relief, and avoid irreversible compliance investments tied to a rule that may not arrive.

Enforcement will vary. Expect inconsistency across U.S. Attorneys' offices, state regulators, and IRS field agents. This remains unsettled.